The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma.
 
Anne L. Thomas
Speakers' Bureau - Roche Pharma AG
 
Martin McKinlay Eatock
Consulting or Advisory Role - Lilly
Speakers' Bureau - Abbott Diagnostics; Pfizer
Research Funding - AstraZeneca (Inst); Boston Biomedical (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Novartis
 
Nick Coupe
No Relationships to Disclose
 
Naomi McGregor
No Relationships to Disclose
 
Sharon Love
No Relationships to Disclose
 
Cristian Ciria
No Relationships to Disclose
 
Linda Collins
No Relationships to Disclose
 
Cathy McDowell
No Relationships to Disclose
 
Mark R. Middleton
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Immunocore; Merck; Roche Pharma AG
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck; Roche Pharma AG